Centanafadine
| Site | IC50 | Action | Ref |
| 83 nM | Blocker | |
| 6 nM | Blocker | |
| 38 nM | Blocker | |
Centanafadine is a serotonin-norepinephrine-dopamine reuptake inhibitor that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.
